ETF DATA OVERVIEW

IBB

Biotechnology

—

What is IBB? Understand the ETF before researching it

Understand its investment scope, concentration, risks and alternatives. This guide is free, with no sign-in required.

1. What do you own?

IBB provides exposure to Biotechnology. Fund units are different from direct ownership of each constituent. This investment scope is not the entire stock market; eligible businesses and actual weights depend on the fund’s current rules and holdings.

2. Many holdings can still mean concentration

Review top holdings, countries and business exposures, not only the company count. Similar ETF names do not imply identical portfolios. Compare XBI / XLV / SPY by actual holdings and selection rules; combining overlapping funds may increase concentration.

3. Where do returns come from?

Earnings, valuation changes and distributions influence returns; expenses reduce them. Price return excludes reinvested distributions. Compare total returns over identical dates and currencies, and check current issuer fees, spreads and trading costs.

4. Understand the downside

Business cycles, interest rates, regulation and changing expectations can cause losses. A 20% loss needs a 25% gain to recover; a 50% loss needs 100%. Sector and thematic funds can remain concentrated despite holding many companies. Dividend payments do not protect capital.

5. A practical research checklist

Start with portfolio role, overlap and loss tolerance. Combine earnings and valuation rather than treating a price decline as proof of value. TTM measures reported past earnings, Forward depends on forecasts; a historical percentile is not a forecast probability.

6. Common questions

Can this ETF lose money? Yes. Does a low share price mean cheap valuation? No. Is this identical to a related ETF? Check the current portfolio. A 52-week drawdown differs from an all-time drawdown. VIX measures S&P 500 option expectations, not this ETF’s own implied volatility.

Free educational information, not personalized investment advice. Data dates and estimate labels remain important.

Is IBB expensive or cheap? How to read PE percentiles

ETF-Investor compares current PE with its own comparable historical observations to place valuation in context. A lower percentile means lower valuation relative to that sample, not a price bottom or a probability of gains.

Available history varies by asset. Forward PE percentiles require comparable forecast history. Exact values, historical windows and deeper research follow account access. PE percentile methodology

IBB · Public data & holdings research

Assets
10.44B USD
Dividend yield
0.20%
TTM PE
25.31×
From 52-week high
-8.35%
Expense ratio
0.44%

Market: 2026-11-19 · Assets: — · Earnings basis: 2026-10-07. TTM PE may be estimated; dates and definitions may differ. Not a trading recommendation.

Research the holdings

Holdings date: 2026-10-02

PRICE CONTEXT

Market movement

DATA QUALITY

Coverage & methodology

General market information only. Values may use different provider methodologies and observation dates. Not investment advice.

ETF-Investor / ETF research

IBB iShares Biotechnology ETF

U.S. biotechnology. Review performance, valuation and holdings together.

$203.72-0.81%2026-11-19 · Close reference

01Recent performance

PeriodReturnHistorical percentileStatus
Daily-0.81%23.87%Typical range
Week to date-4.13%5.35%Unusually weak
Month to date-6.38%6.72%Unusually weak
Year to date+20.71%
From 52-week high-8.35%
Price history
221.132025-11-182026-11-19203.72

02How expensive is IBB?

Historical TTM valuation
Current TTM PE25.31×
Historical percentile—
Valuation zone—
No comparable percentile is available; the marker is withheld.

Earnings outlook

No verified forward valuation is currently available.

View historical PE chart

History unavailable

Data dates and notes

Prices: 2026-11-19;TTM PE: 2026-11-19;Forward:2026-10-07。

03What to consider now

Existing holders

Consider existing exposure and the long-term business rather than reacting to one price move.

Considering a purchase

Wait for a qualifying opportunity; a short-term decline does not necessarily mean good value.

The scale describes valuation context. Opportunity screens use the existing complete rules and are not personalized trading instructions.

04Top holdings

Holdings date 2026-10-02
TickerDailyMarket capWeightIV30TTM PEPE percentileForward PEEPS growthForward percentile52W drawdownYTDFollow
GILD-1.45%$206.55B8.05%32.22%——16.47×——-5.69%35.68%
AMGN-1.14%$237.36B7.63%29.77%25.44×86.25%17.52×7.15%—-9.33%34.07%
VRTX-2.94%$132.01B7.54%34.31%33.50×67.54%29.05×11.30%—-8.44%14.84%
REGN-2.35%$95.52B5.25%33.25%20.41×39.05%14.71×7.78%—-6.90%19.62%
MRNA+1.29%$80.65B5.00%82.97%—————-29.01%575.92%
NTRA+0.15%$42.04B3.98%56.63%——40479.00×——-33.72%26.55%
ARGX+0.08%$59.24B3.68%43.57%32.63×9.52%26.80×24.42%—-12.18%12.02%
ILMN-4.45%$30.34B2.96%56.91%34.54×5.70%32.31×14.36%—-35.14%52.98%
RVMD-0.24%$34.48B2.87%55.54%—————-28.92%100.16%
BIIB-1.70%$36.53B2.32%54.71%106.98×99.17%15.50×27.93%—-5.31%40.42%

05Understand IBB

Read the core research first; expand these references when needed.

What you own

IBB provides exposure to Biotechnology. Fund units are different from direct ownership of each constituent. This investment scope is not the entire stock market; eligible businesses and actual weights depend on the fund’s current rules and holdings.

What makes it different

Review top holdings, countries and business exposures, not only the company count. Similar ETF names do not imply identical portfolios. Compare XBI / XLV / SPY by actual holdings and selection rules; combining overlapping funds may increase concentration.

Where returns come from

Earnings, valuation changes and distributions influence returns; expenses reduce them. Price return excludes reinvested distributions. Compare total returns over identical dates and currencies, and check current issuer fees, spreads and trading costs.

Risks and what to watch

Business cycles, interest rates, regulation and changing expectations can cause losses. A 20% loss needs a 25% gain to recover; a 50% loss needs 100%. Sector and thematic funds can remain concentrated despite holding many companies. Dividend payments do not protect capital.

Related ETFs and sources

Explore ETFs

iShares Biotechnology ETF · Fund information

Existing research tools

Open the original research page →

For research only. This research is not personal investment advice.

PASSWORD-FREE ACCESS

Continue with email

We’ll send you a secure sign-in link. No password required.

By continuing, you agree to the Terms and acknowledge the Privacy Policy.